Search
Research
Pertussis burden and acellular pertussis vaccine effectiveness in high risk childrenPertussis hospitalisation is more common among infants born prematurely, who have significant comorbidities, or are Indigenous, but acellular pertussis (aP) vaccine effectiveness (VE) estimates in these sub-groups are lacking. We measured aP VE by Indigenous status, and policy-relevant categories of prematurity and comorbidity, in a population-based Australian cohort.
Research
A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancyData on systemic and local reactions following receipt of TIV and dTpa during pregnancy support the safety of antenatal vaccination
Research
How Accurate Are International Classification of Diseases-10 Diagnosis Codes in Detecting Influenza and Pertussis Hospitalizations in Children?Influenza diagnosis codes had high specificity (98.6%) and modest positive predictive value (PPV; 84.1%) and sensitivity (86.1%) for a laboratory-confirmed...

News & Events
Warm Welcome for the Neonatal Infection and Immunity TeamClinical Professor Tobias Strunk, Dr Andrew Currie and their Neonatal Infection and Immunity Team have become the newest members of the Wesfarmers Centre of Vaccines and Infectious Diseases.
Research
The effectiveness of maternal pertussis vaccination for protecting Aboriginal and Torres Strait Islander infants against infection, 2012–2017: a retrospective cohort studyTo evaluate the effectiveness of maternal pertussis vaccination for preventing pertussis infections in Aboriginal and Torres Strait Islander infants under seven months of age.

News & Events
Researchers share their expertise with the community in CockburnResearchers from the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia have shared their expertise with the community in Cockburn, covering topics ranging from respiratory disease in babies to recurring ear infections in kids.
Research
Acellular Pertussis Vaccine Given in the Week After Birth Does Not Impair Antibody Responses to Later Childhood DosesA birth acellular pertussis vaccine may be a valuable alternative for immunity against infant pertussis when a pregnancy pertussis vaccine has not been administered. We assessed whether a birth dose may impair immunoglobulin G (IgG) responses to childhood pertussis boosters.
Research
Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccinesWe compared the effect of a heterologous wP/aP/aP primary series (hereafter mixed wP/aP) versus a homologous aP/aP/aP primary schedule (hereafter aP-only) on antibody responses to co-administered vaccine antigens in infants and toddlers.
Research
Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical TrialThe monovalent acellular pertussis vaccine is immunogenic and safe in neonates
Research
Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birthIn the longest reported follow-up of infants who received aP vaccine at birth, we found a trend to lower PT IgG antibodies post booster compared with receipt...